Icosapent ethyl Reference

Plain English

What it is

Icosapent ethyl is a prescription medicine sold under the brand name Vascepa. It is a purified form of an omega-3 fatty acid (called EPA) that comes from fish oil, and it is approved by the FDA.

What people use it for

It is approved to lower very high blood fats called triglycerides, and to lower the chance of heart problems like heart attack and stroke in certain adults who are already on a statin (a common cholesterol medicine).

What the science shows

In a large trial called REDUCE-IT, more than eight thousand people on a statin took either this medicine or a dummy pill for about five years. Those on the medicine had roughly a quarter fewer major heart events, which is what led the FDA to expand the approved uses.

The catch

Prescription Vascepa is not the same as the over-the-counter fish oil sold in stores. Its label warns it can raise the chance of an irregular heartbeat (atrial fibrillation) and of bleeding. Researchers have also argued over the dummy pill used in the main trial, and a separate study with a different fish oil blend found no heart benefit, so the picture is not fully settled.

Reference summary

REDUCE-IT (Bhatt 2019 NEJM, n=8,179) randomized statin-treated patients with elevated triglycerides to icosapent ethyl 4 g/day vs mineral oil placebo and reported a 25 percent relative reduction in the primary composite cardiovascular endpoint over a median 4.9 years. The mineral-oil-placebo comparator has been a source of methodological debate (STRENGTH was neutral with a different EPA+DHA formulation, raising questions about whether the REDUCE-IT signal is fully attributable to icosapent ethyl). Both controversies are summarized in the pepSmart omega-3 cardiovascular evidence article.

Regulatory and posture

Categories

Metabolic

Aliases

Vascepa, Ethyl eicosapentaenoate, Highly purified EPA ethyl ester (small molecule, not a peptide)

Evidence posture

human

Regulatory status

FDA-approved as Vascepa (2012) for severe hypertriglyceridemia (TG at or above 500 mg/dL) and (2019, label expansion) for cardiovascular event reduction as an adjunct to maximally tolerated statin therapy in adults with TG at or above 150 mg/dL plus either established cardiovascular disease or diabetes plus at least 2 additional CV risk factors.

Content review status

label verified